Clinical Trials Logo

Clinical Trial Summary

Curative treatment for oesophageal cancer involves undertaking chemotherapy followed by an operation to remove the tumour. Chemotherapy has several effects upon the body, including effects upon the systems that control the creation and breakdown of muscle. We aim to review these effects by recording changes in the amount of exercise patients are able to undertake after chemotherapy and reviewing changes in muscle mass.


Clinical Trial Description

We aim to review the effects of chemotherapy on skeletal muscle mass and cardio-respiratory performance in patients with oesophageal adenocarcinoma. All patients will be assessed by a Consultant Anaesthetist and a medical member of the Research team before commencing chemotherapy and after finishing their course. These assessments include a nutritional assessment, performance status assessments, blood assays, dual energy X-ray absorptiometry (DEXA) scans, cardio-pulmonary exercise (CPEX) testing and a muscle biopsy. ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01742312
Study type Observational
Source University of Nottingham
Contact
Status Completed
Phase N/A
Start date October 2011
Completion date January 2013

See also
  Status Clinical Trial Phase
Recruiting NCT02962219 - Exercise Prior to Oesophagectomy N/A
Recruiting NCT03626610 - Prehabilitation of Patients With oEsophageal Malignancy Undergoing Peri-operative Treatment N/A
Suspended NCT05135845 - Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma Phase 2
Active, not recruiting NCT03399071 - Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer Phase 2
Active, not recruiting NCT04554771 - Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy Phase 2
Active, not recruiting NCT05104567 - A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) Phase 2
Completed NCT03641547 - M6620 Plus Standard Treatment in Oesophageal and Other Cancer Phase 1
Recruiting NCT06289374 - Longitudinal Assessment of Biomarkers After Oesophagogastric Cancer Surgery